FDA approves patisiran to treat hereditary transthyretin amyloidosis
Crossref DOI link: https://doi.org/10.1038/s41582-018-0065-0
Published Online: 2018-08-29
Published Print: 2018-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wood, Heather
Text and Data Mining valid from 2018-08-29
Article History
First Online: 29 August 2018